DUBLIN, Ireland, and Boston MA, July 7, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, presented new positive analyses from EASE at the 2022 Society for Pediatric...
TW's Take: positive news for AMYT as they now have a 4th product on the market. This is a sleeper stock with solid growth and a low valuation.
DUBLIN, Ireland, and Boston MA, June 23, 2022, Amryt (Nasdaq: AMYT), a...
DUBLIN, Ireland, and Boston MA, June 13, 2022 - Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, presented positive clinical data from the open-label extensions (OLEs) of two...
DUBLIN, Ireland, and Boston MA, June 8, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announced that it will be presenting positive data from two Phase...
This past week in Charlottesville, The Boar's Head Women's Open took place. This is an annual tennis tournament featuring 32 professional tennis players, most of whom are ranked in the top 250 in the world. Several past winners of...
TW's Take: good news for a product that had been basically taken out of Wall Street's models.
DUBLIN, Ireland, and Boston MA, April 22, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel...
TW's Take: Mycapssa will likely be a blockbuster for Amryt in the next few years. The data is compelling and the oral versus injectable will win market share all day long.
DUBLIN, Ireland, and Boston MA, April 13, 2022, Amryt...
TW's Take: it appears, now that Oleogel has failed, that the worst is over for Amryt and the value of the company will become evident through strong sales growth, cash flow generation and expanded opportunities for current products.
DUBLIN, Ireland,...
TW's Take: positive news as the opportunity in NET is substantial and an oral solution would be greatly preferred by doctors and patients alike.
DUBLIN, Ireland, and Boston MA, March 8, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company...
TW's Take: an expected outcome post the first CRL received by the Company. I believe this removes the overhang and investors can now focus on the great value here along with accelerating growth.
DUBLIN, Ireland, and Boston, MA, February 28,...
By the time you read this newsletter, there's a good chance that the Ukraine will be begging for a ceasefire and, basically, surrendering to Russia. The lines are being redrawn on the next cold war, reinforcing the two facts...
TW's Take: we continue to be concerned over the likelihood of Oleogel approval but find Amryt compelling based on approved products and its current valuation. Would be a buyer post the upcoming FDA decision on Oleogel.
DUBLIN, Ireland, and Boston...
TW's Take: we believe that Mycapssa's unique oral delivery versus the competition will drive substantial sales for the product. Amryt is a compelling risk/reward opportunity but we remain concerned about the company's upcoming PDUFA date on Oleogel S-10 and...
Investing in micro-cap stocks with a 3-5 year time horizon, which is my expectation for a holding period every time I enter a position, will by definition result in lots of volatility. That was certainly the case in 2021,...
TW's Take: this request for additional information certainly increases the risks around the Oleogel PDUFA. Amryt is a reasonably priced stock even if it gets rejected.
DUBLIN, Ireland, and Boston MA, November 23, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a...
DUBLIN, Ireland, and Boston MA, November 22, 2021, Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) (“Amryt” or the “Company”), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces its intention to cancel the admission...
TW's Take: still firing on all cylinders. Nov. 30th PDUFA date is key for Amryt. Approval of Oleogel gives them a PRV worth $100 million and a product with $1B potential. If approved, I expect the stock to more...
TW's Take: nice to see these patents issued. More importantly, however, we are approaching the PDUFA date for Oleogel. With AMYT languishing around $12, the stock is a great risk/reward at this time.
DUBLIN, Ireland, and Boston MA, October 19,...
September to remember? I had such high hopes. Sadly, it turned out to be a very forgettable month and I'm happy to have it behind me.
I was concerned about the market going into the historically weakest month of the...
The markets had another downward-trending week since the last newsletter. However, the overall tone of the market felt better from a micro-cap investing standpoint and my bi-polar attitude (loving my stocks, not liking the market) feels rather appropriate. Despite...
TW's Take: good news that we expected would come as the Company continues to execute very well. The Chiasma acquisition will lead to much higher revenues over the next couple years and if their, very important, PDUFA date for...
While the bankers and fund managers are heading out to the Hamptons for vacation, micro-cap earnings season kicked in last week and news flow in general seems to be picking up. I've been saying that the 2nd half of...
If you've been reading this newsletter for longer than two weeks, you likely have come to realize that I'm an investor not a trader. Quite simply, my philosophy is to look for stocks that have the potential to return...
TW's Take: another quarter of excellent results and raised guidance. Amryt is firing on all cylinders. With the acquisition of Chiasma officially completed, expect to see revenues continue to increase rapidly and guidance adjusted higher. Oleogel approval and this...
The "bull" market continued this past week although it showed signs of tiring. Which is good because the bull ride we've been on resembles one at the Calgary Stampede. While the S&P 500 hits new highs, micro-cap growth is...
As the market seems to be slowly settling into summer, volatility is dropping and news flow is getting sparse. Amazing to think this is the last newsletter before the 4th of July. The pandemic seemed to drag on forever...
It was another great week for TW as the pendulum appears to be swinging full speed in our direction. This while the overall market continues to push to new highs and all eyes remain fixated on the Fed, inflation,...
TW's Take: more good news on Oleogel-S10. If the drug is approved, as expected, AMYT is a bargain at current prices.
DUBLIN, Ireland, and Boston MA, June 7, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated...
Greetings from Ashland, Oregon where my tour of the west coast is ending in fine fashion. The biking here is outstanding, the meals our crew cooks up are incredible but the ability to write a coherent newsletter is rather...
TW's Take: this is excellent news and positions AMYT for a big move in the second half of 2021. With the Chiasma acquisition, if the EB drug is approved, Amryt will be generating a LOT of free cash-flow over...
TW's Take: continued positive execution for Amryt. We hope to see priority review designation with approval later this year. AMYT should move higher into the PDUFA date as they are extremely undervalued and the clinical results are highly supportive...
The pandemic-inspired rally of 2020 was an unexpected surprise for many companies, particularly those in biotech, which soared last year. The access to capital, low interest rates and government spending on Covid programs led to a major rally in...
Okay, I was early. I admit it. But, unless growth stocks never rally again, biotech in particular, I'm 100% convinced that buying at these levels is absolutely the right thing to be doing.
Check out where my stocks are trading...
TW's Take: nice to see the guidance increased and it's obvious that the core business is going very well at Amryt, but the key today is their acquisition of Chiasma, a deal we love.
8.7% YoY revenue growth in...
TW's Take: we have been expecting Amryt to make an acquisition and this one is exciting. The prospects for MYCAPSSA are quite strong and the synergies between the two firms are outstanding. Amryt's big date is later this year...
DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Sheila Frame as President...
My wife and I spent Good Friday in the car, driving up to Massachusetts to visit my number one newsletter fan; my mother. It was a long day but certainly well worth the effort.
The drive was eerily reminiscent of...
TW's Take: if approved, Oleogel-S10 is likely to become Amryt's largest drug franchise in very short order. Expect to hear about the acceptance and priority review status in Q2. Possible Priority Review Voucher grant in Q4 as well, which...
TW's Take: very encouraging data as a label expansion into FCS would potentially double the addressable market for the drug. Amryt continues to increase the value of their existing franchises while moving forward on their potentially blockbuster EB product,...
TW's Take: further progress as they march towards hopeful approval in EB, which should make Oleogel-S10 their largest product in short order.
DUBLIN, Ireland, and Boston MA, March 29, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company...
TW's Take: very positive step forward in broadening the indications for Myalept. Management of Amryt continues to execute well and the stock remains deeply discounted relative to its peer group.
DUBLIN, Ireland, and Boston MA, March 23, 2021, Amryt (Nasdaq:...
TW's Take: this further expands the market opportunity for Myalepta, allowing continued growth of this franchise. We remain excited about AMYT as the expected approval of their EB therapeutic later in 2021 approaches.
DUBLIN, Ireland, and Boston MA, March 22,...
TW's Take: Amryt's team has continually demonstrated positive progress in expanding their existing franchises.
DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for...
Good Morning Vietnam!
Okay, I'll confess to exaggerating a little; I neither live nor work in a war zone. It only just felt like someone was taking napalm to my portfolio on a daily basis the last couple weeks....
Growing nicely and trading under 20 times 2020 EBITDA, Amryt Pharma (AMYT) has somehow managed to build a global franchise in rare diseases yet to stay off of most investors’ radar screens. However, with a big catalyst coming later...